Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study (Q43613438)

25 November 2017

Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study (English)

1 reference

25 November 2017

1 reference

6

1 reference

25 November 2017

Jackie Curtis

1

1 reference

25 November 2017

Catherine Henry

2

1 reference

25 November 2017

Andrew Watkins

3

1 reference

25 November 2017

Hannah Newall

4

1 reference

25 November 2017

Katherine Samaras

5

1 reference

25 November 2017

7 April 2011

1 reference

Early Intervention in Psychiatry: the development, onset and treatment of emerging mental disorders

25 November 2017

1 reference

25 November 2017

5

1 reference

25 November 2017

2

1 reference

25 November 2017

108-114

1 reference

Severe mental illness and risk of cardiovascular disease

25 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Abnormal glucose metabolism in patients treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Weight gain in first-episode psychosis over three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Metabolic profile of antipsychotic-naive individuals with non-affective psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Metabolic risk factors in drug-naive patients with first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-7893.2011.00262.X

10.1111/J.1751-7893.2011.00262.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference